ID   PTPRC_HUMAN             Reviewed;        1304 AA.
AC   P08575; A8K7W6; Q16614; Q9H0Y6;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2003, sequence version 2.
DT   10-MAY-2017, entry version 202.
DE   RecName: Full=Receptor-type tyrosine-protein phosphatase C;
DE            EC=3.1.3.48;
DE   AltName: Full=Leukocyte common antigen;
DE            Short=L-CA;
DE   AltName: Full=T200;
DE   AltName: CD_antigen=CD45;
DE   Flags: Precursor;
GN   Name=PTPRC; Synonyms=CD45;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING.
RC   TISSUE=Lymphocyte;
RX   PubMed=2824653; DOI=10.1084/jem.166.5.1548;
RA   Streuli M., Hall L.R., Saga Y., Schlossman S.F., Saito H.;
RT   "Differential usage of three exons generates at least five different
RT   mRNAs encoding human leukocyte common antigens.";
RL   J. Exp. Med. 166:1548-1566(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=2956090;
RA   Ralph S.J., Thomas M.L., Morton C.C., Trowbridge I.S.;
RT   "Structural variants of human T200 glycoprotein (leukocyte-common
RT   antigen).";
RL   EMBO J. 6:1251-1257(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 146-192.
RX   PubMed=2531281; DOI=10.1128/MCB.9.10.4550;
RA   Tsai A.Y.M., Streuli M., Saito H.;
RT   "Integrity of the exon 6 sequence is essential for tissue-specific
RT   alternative splicing of human leukocyte common antigen pre-mRNA.";
RL   Mol. Cell. Biol. 9:4550-4555(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 191-1304.
RC   TISSUE=Placenta;
RX   PubMed=2971730;
RA   Hall L.R., Streuli M., Schlossman S.F., Saito H.;
RT   "Complete exon-intron organization of the human leukocyte common
RT   antigen (CD45) gene.";
RL   J. Immunol. 141:2781-2787(1988).
RN   [6]
RP   FUNCTION.
RX   PubMed=2845400; DOI=10.1073/pnas.85.19.7182;
RA   Charbonneau H., Tonks N.K., Walsh K.A., Fischer E.H.;
RT   "The leukocyte common antigen (CD45): a putative receptor-linked
RT   protein tyrosine phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:7182-7186(1988).
RN   [7]
RP   MUTAGENESIS.
RX   PubMed=1695146;
RA   Streuli M., Krueger N.X., Thai T., Tang M., Saito H.;
RT   "Distinct functional roles of the two intracellular phosphatase like
RT   domains of the receptor-linked protein tyrosine phosphatases LCA and
RT   LAR.";
RL   EMBO J. 9:2399-2407(1990).
RN   [8]
RP   INTERACTION WITH SKAP1, MUTAGENESIS OF CYS-851, AND FUNCTION.
RX   PubMed=11909961; DOI=10.1128/MCB.22.8.2673-2686.2002;
RA   Wu L., Fu J., Shen S.-H.;
RT   "SKAP55 coupled with CD45 positively regulates T-cell receptor-
RT   mediated gene transcription.";
RL   Mol. Cell. Biol. 22:2673-2686(2002).
RN   [9]
RP   INTERACTION WITH DPP4, AND SUBCELLULAR LOCATION.
RX   PubMed=12676959; DOI=10.1074/jbc.M212978200;
RA   Salgado F.J., Lojo J., Alonso-Lebrero J.L., Lluis C., Franco R.,
RA   Cordero O.J., Nogueira M.;
RT   "A role for interleukin-12 in the regulation of T cell plasma membrane
RT   compartmentation.";
RL   J. Biol. Chem. 278:24849-24857(2003).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-973, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-232 AND ASN-335.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-232; ASN-240; ASN-276;
RP   ASN-284; ASN-335; ASN-419; ASN-488 AND ASN-497.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-973 AND SER-1297, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL11.
RX   PubMed=22174689; DOI=10.1371/journal.ppat.1002432;
RA   Gabaev I., Steinbrueck L., Pokoyski C., Pich A., Stanton R.J.,
RA   Schwinzer R., Schulz T.F., Jacobs R., Messerle M., Kay-Fedorov P.C.;
RT   "The human cytomegalovirus UL11 protein interacts with the receptor
RT   tyrosine phosphatase CD45, resulting in functional paralysis of T
RT   cells.";
RL   PLoS Pathog. 7:E1002432-E1002432(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-973 AND SER-992, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 622-1231 ALONE AND IN COMPLEX
RP   WITH PHOSPHOPEPTIDE.
RX   PubMed=15684325; DOI=10.1084/jem.20041890;
RA   Nam H.J., Poy F., Saito H., Frederick C.A.;
RT   "Structural basis for the function and regulation of the receptor
RT   protein tyrosine phosphatase CD45.";
RL   J. Exp. Med. 201:441-452(2005).
RN   [19]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO MS.
RX   PubMed=11101853; DOI=10.1038/82659;
RA   Jacobsen M., Schweer D., Ziegler A., Gaber R., Schock S.,
RA   Schwinzer R., Wonigeit K., Lindert R.-B., Kantarci O.,
RA   Schaefer-Klein J., Schipper H.I., Oertel W.H., Heidenreich F.,
RA   Weinshenker B.G., Sommer N., Hemmer B.;
RT   "A point mutation in PTPRC is associated with the development of
RT   multiple sclerosis.";
RL   Nat. Genet. 26:495-499(2000).
RN   [20]
RP   VARIANT T(-)B(+)NK(+) SCID 362-GLU-TYR-363 DEL, AND CHARACTERIZATION
RP   OF VARIANT T(-)B(+)NK(+) SCID 362-GLU-TYR-363 DEL.
RX   PubMed=11145714; DOI=10.4049/jimmunol.166.2.1308;
RA   Tchilian E.Z., Wallace D.L., Wells R.S., Flower D.R., Morgan G.,
RA   Beverley P.C.L.;
RT   "A deletion in the gene encoding the CD45 antigen in a patient with
RT   SCID.";
RL   J. Immunol. 166:1308-1313(2001).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-228 AND ARG-863.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Protein tyrosine-protein phosphatase required for T-cell
CC       activation through the antigen receptor. Acts as a positive
CC       regulator of T-cell coactivation upon binding to DPP4. The first
CC       PTPase domain has enzymatic activity, while the second one seems
CC       to affect the substrate specificity of the first one. Upon T-cell
CC       activation, recruits and dephosphorylates SKAP1 and FYN.
CC       Dephosphorylates LYN, and thereby modulates LYN activity (By
CC       similarity). {ECO:0000250, ECO:0000269|PubMed:11909961,
CC       ECO:0000269|PubMed:2845400}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- SUBUNIT: Binds GANAB and PRKCSH (By similarity). Interacts with
CC       SKAP1. Interacts with DPP4; the interaction is enhanced in a
CC       interleukin-12-dependent manner in activated lymphocytes.
CC       Interacts with human cytomegalovirus protein UL11. {ECO:0000250,
CC       ECO:0000269|PubMed:11909961, ECO:0000269|PubMed:12676959,
CC       ECO:0000269|PubMed:15684325, ECO:0000269|PubMed:22174689}.
CC   -!- INTERACTION:
CC       P41240:CSK; NbExp=3; IntAct=EBI-1341, EBI-1380630;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-1341, EBI-491549;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-1341, EBI-641062;
CC       P20701:ITGAL; NbExp=2; IntAct=EBI-1341, EBI-961214;
CC       P06239:LCK; NbExp=7; IntAct=EBI-1341, EBI-1348;
CC       P06240:Lck (xeno); NbExp=2; IntAct=EBI-1341, EBI-1401;
CC       P09382:LGALS1; NbExp=2; IntAct=EBI-1341, EBI-1048875;
CC       Q02763:TEK; NbExp=3; IntAct=EBI-1341, EBI-2257090;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:12676959};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:12676959}.
CC       Membrane raft {ECO:0000269|PubMed:12676959}. Note=Colocalized with
CC       DPP4 in membrane rafts.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=At least 8 isoforms are produced.;
CC       Name=1;
CC         IsoId=P08575-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08575-2; Sequence=VSP_007780;
CC   -!- DOMAIN: The first PTPase domain interacts with SKAP1.
CC   -!- PTM: Heavily N- and O-glycosylated. {ECO:0000269|PubMed:19159218,
CC       ECO:0000269|PubMed:19349973}.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-
CC       cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+)
CC       SCID) [MIM:608971]: A form of severe combined immunodeficiency
CC       (SCID), a genetically and clinically heterogeneous group of rare
CC       congenital disorders characterized by impairment of both humoral
CC       and cell-mediated immunity, leukopenia, and low or absent antibody
CC       levels. Patients present in infancy recurrent, persistent
CC       infections by opportunistic organisms. The common characteristic
CC       of all types of SCID is absence of T-cell-mediated cellular
CC       immunity due to a defect in T-cell development.
CC       {ECO:0000269|PubMed:11145714}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Multiple sclerosis (MS) [MIM:126200]: A multifactorial,
CC       inflammatory, demyelinating disease of the central nervous system.
CC       Sclerotic lesions are characterized by perivascular infiltration
CC       of monocytes and lymphocytes and appear as indurated areas in
CC       pathologic specimens (sclerosis in plaques). The pathological
CC       mechanism is regarded as an autoimmune attack of the myelin
CC       sheath, mediated by both cellular and humoral immunity. Clinical
CC       manifestations include visual loss, extra-ocular movement
CC       disorders, paresthesias, loss of sensation, weakness, dysarthria,
CC       spasticity, ataxia and bladder dysfunction. Genetic and
CC       environmental factors influence susceptibility to the disease.
CC       {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Receptor class 1/6 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=PTPRCbase; Note=PTPRC mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/PTPRCbase/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD45 entry;
CC       URL="https://en.wikipedia.org/wiki/CD45";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y00638; CAA68669.1; -; mRNA.
DR   EMBL; Y00062; CAA68269.1; -; mRNA.
DR   EMBL; AK292131; BAF84820.1; -; mRNA.
DR   EMBL; M23492; AAD15273.2; -; Genomic_DNA.
DR   EMBL; M23496; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23466; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23467; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23468; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23469; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23470; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23471; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23472; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23473; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23474; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23475; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23476; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23477; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23478; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23479; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23480; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23481; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23482; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23483; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23484; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23485; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23486; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23487; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23488; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23489; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23490; AAD15273.2; JOINED; Genomic_DNA.
DR   EMBL; M23491; AAD15273.2; JOINED; Genomic_DNA.
DR   PIR; A46546; A46546.
DR   RefSeq; NP_002829.3; NM_002838.4.
DR   RefSeq; NP_563578.2; NM_080921.3.
DR   UniGene; Hs.654514; -.
DR   PDB; 1YGR; X-ray; 2.90 A; A/B=622-1231.
DR   PDB; 1YGU; X-ray; 2.90 A; A/B=622-1231.
DR   PDB; 5FMV; X-ray; 2.90 A; A/B=223-571.
DR   PDB; 5FN6; X-ray; 3.30 A; A=223-479.
DR   PDB; 5FN7; X-ray; 2.30 A; A/B=223-392.
DR   PDBsum; 1YGR; -.
DR   PDBsum; 1YGU; -.
DR   PDBsum; 5FMV; -.
DR   PDBsum; 5FN6; -.
DR   PDBsum; 5FN7; -.
DR   ProteinModelPortal; P08575; -.
DR   SMR; P08575; -.
DR   BioGrid; 111752; 24.
DR   DIP; DIP-224N; -.
DR   IntAct; P08575; 39.
DR   MINT; MINT-1130341; -.
DR   STRING; 9606.ENSP00000356346; -.
DR   BindingDB; P08575; -.
DR   ChEMBL; CHEMBL3243; -.
DR   DEPOD; P08575; -.
DR   iPTMnet; P08575; -.
DR   PhosphoSitePlus; P08575; -.
DR   SwissPalm; P08575; -.
DR   UniCarbKB; P08575; -.
DR   BioMuta; PTPRC; -.
DR   DMDM; 33112650; -.
DR   EPD; P08575; -.
DR   MaxQB; P08575; -.
DR   PaxDb; P08575; -.
DR   PeptideAtlas; P08575; -.
DR   PRIDE; P08575; -.
DR   Ensembl; ENST00000367376; ENSP00000356346; ENSG00000081237.
DR   Ensembl; ENST00000573477; ENSP00000461074; ENSG00000262418.
DR   Ensembl; ENST00000573679; ENSP00000458322; ENSG00000262418.
DR   Ensembl; ENST00000594404; ENSP00000471843; ENSG00000081237.
DR   GeneID; 5788; -.
DR   KEGG; hsa:5788; -.
DR   UCSC; uc061fse.1; human. [P08575-1]
DR   CTD; 5788; -.
DR   DisGeNET; 5788; -.
DR   GeneCards; PTPRC; -.
DR   HGNC; HGNC:9666; PTPRC.
DR   HPA; HPA000440; -.
DR   MalaCards; PTPRC; -.
DR   MIM; 126200; phenotype.
DR   MIM; 151460; gene.
DR   MIM; 608971; phenotype.
DR   neXtProt; NX_P08575; -.
DR   Orphanet; 169157; T-B+ severe combined immunodeficiency due to CD45 deficiency.
DR   PharmGKB; PA34011; -.
DR   eggNOG; KOG4228; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   HOGENOM; HOG000049064; -.
DR   HOVERGEN; HBG000066; -.
DR   InParanoid; P08575; -.
DR   KO; K06478; -.
DR   OrthoDB; EOG091G015A; -.
DR   PhylomeDB; P08575; -.
DR   TreeFam; TF351829; -.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-416700; Other semaphorin interactions.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; P08575; -.
DR   SIGNOR; P08575; -.
DR   ChiTaRS; PTPRC; human.
DR   EvolutionaryTrace; P08575; -.
DR   GeneWiki; PTPRC; -.
DR   GenomeRNAi; 5788; -.
DR   PRO; PR:P08575; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000081237; -.
DR   CleanEx; HS_PTPRC; -.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0005001; F:transmembrane receptor protein tyrosine phosphatase activity; TAS:ProtInc.
DR   GO; GO:0042100; P:B cell proliferation; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048539; P:bone marrow development; IMP:UniProtKB.
DR   GO; GO:0044770; P:cell cycle phase transition; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0051607; P:defense response to virus; ISS:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IMP:UniProtKB.
DR   GO; GO:0002378; P:immunoglobulin biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006933; P:negative regulation of cell adhesion involved in substrate-bound cell migration; IMP:UniProtKB.
DR   GO; GO:0001960; P:negative regulation of cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0001915; P:negative regulation of T cell mediated cytotoxicity; ISS:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0050857; P:positive regulation of antigen receptor-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:2000473; P:positive regulation of hematopoietic stem cell migration; IMP:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; NAS:UniProtKB.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:UniProtKB.
DR   GO; GO:0042102; P:positive regulation of T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; ISS:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0048864; P:stem cell development; IMP:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.90.190.10; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR024739; PTP_recept_N.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR016335; Ptprc.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF12567; CD45; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF12453; PTP_N; 1.
DR   Pfam; PF00102; Y_phosphatase; 2.
DR   PIRSF; PIRSF002004; Leukocyte_common_antigen; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00194; PTPc; 2.
DR   SMART; SM00404; PTPc_motif; 2.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF52799; SSF52799; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 2.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Glycoprotein; Hydrolase; Membrane; Phosphoprotein;
KW   Polymorphism; Protein phosphatase; Reference proteome; Repeat; SCID;
KW   Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     23
FT   CHAIN        24   1304       Receptor-type tyrosine-protein
FT                                phosphatase C.
FT                                /FTId=PRO_0000025470.
FT   TOPO_DOM     24    575       Extracellular. {ECO:0000255}.
FT   TRANSMEM    576    597       Helical. {ECO:0000255}.
FT   TOPO_DOM    598   1304       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      389    481       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      482    574       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      651    910       Tyrosine-protein phosphatase 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   DOMAIN      942   1226       Tyrosine-protein phosphatase 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      851    857       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    851    851       Phosphocysteine intermediate.
FT   ACT_SITE   1167   1167       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   BINDING     819    819       Substrate. {ECO:0000250}.
FT   BINDING     895    895       Substrate. {ECO:0000250}.
FT   MOD_RES     681    681       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     973    973       Phosphoserine.
FT                                {ECO:0000244|PubMed:19367720,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     992    992       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     995    995       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES     999    999       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES    1002   1002       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES    1003   1003       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P06800}.
FT   MOD_RES    1007   1007       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04157}.
FT   MOD_RES    1297   1297       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   CARBOHYD     78     78       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     90     90       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    184    184       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    190    190       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    197    197       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    232    232       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    240    240       N-linked (GlcNAc...) asparagine;
FT                                atypical. {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    260    260       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    270    270       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    276    276       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    284    284       N-linked (GlcNAc...) asparagine;
FT                                atypical. {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    378    378       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    419    419       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    488    488       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    497    497       N-linked (GlcNAc...) asparagine;
FT                                atypical. {ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    529    529       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ      32    192       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:2956090}.
FT                                /FTId=VSP_007780.
FT   VARIANT     191    191       T -> A (in dbSNP:rs4915154).
FT                                /FTId=VAR_036860.
FT   VARIANT     228    228       E -> A (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035653.
FT   VARIANT     294    294       I -> L (in dbSNP:rs2230606).
FT                                /FTId=VAR_051763.
FT   VARIANT     362    363       Missing (in T(-)B(+)NK(+) SCID;
FT                                associated with lack of surface
FT                                expression).
FT                                {ECO:0000269|PubMed:11145714}.
FT                                /FTId=VAR_021205.
FT   VARIANT     421    421       T -> I (in dbSNP:rs6696162).
FT                                /FTId=VAR_051764.
FT   VARIANT     568    568       H -> Q (in dbSNP:rs12136658).
FT                                /FTId=VAR_051765.
FT   VARIANT     863    863       G -> R (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035654.
FT   VARIANT    1283   1283       S -> R (in dbSNP:rs2298872).
FT                                /FTId=VAR_020303.
FT   MUTAGEN     851    851       C->S: Loss of activity. Abolishes
FT                                interaction with SKAP1.
FT                                {ECO:0000269|PubMed:11909961}.
FT   CONFLICT    650    650       L -> P (in Ref. 1; CAA68669).
FT                                {ECO:0000305}.
FT   CONFLICT   1207   1207       P -> L (in Ref. 1; CAA68669).
FT                                {ECO:0000305}.
FT   HELIX       226    229       {ECO:0000244|PDB:5FN7}.
FT   TURN        230    232       {ECO:0000244|PDB:5FN7}.
FT   STRAND      235    240       {ECO:0000244|PDB:5FN7}.
FT   TURN        241    244       {ECO:0000244|PDB:5FN7}.
FT   STRAND      245    250       {ECO:0000244|PDB:5FN7}.
FT   STRAND      257    261       {ECO:0000244|PDB:5FN7}.
FT   HELIX       264    266       {ECO:0000244|PDB:5FN7}.
FT   STRAND      267    271       {ECO:0000244|PDB:5FN7}.
FT   STRAND      276    282       {ECO:0000244|PDB:5FN7}.
FT   STRAND      286    289       {ECO:0000244|PDB:5FN7}.
FT   STRAND      291    296       {ECO:0000244|PDB:5FN7}.
FT   HELIX       301    303       {ECO:0000244|PDB:5FN7}.
FT   STRAND      304    308       {ECO:0000244|PDB:5FN7}.
FT   HELIX       312    314       {ECO:0000244|PDB:5FN7}.
FT   TURN        315    317       {ECO:0000244|PDB:5FN7}.
FT   STRAND      319    325       {ECO:0000244|PDB:5FN7}.
FT   HELIX       333    335       {ECO:0000244|PDB:5FN7}.
FT   STRAND      336    342       {ECO:0000244|PDB:5FN7}.
FT   STRAND      345    354       {ECO:0000244|PDB:5FN7}.
FT   STRAND      362    371       {ECO:0000244|PDB:5FN7}.
FT   STRAND      374    386       {ECO:0000244|PDB:5FN7}.
FT   STRAND      394    399       {ECO:0000244|PDB:5FMV}.
FT   STRAND      401    404       {ECO:0000244|PDB:5FMV}.
FT   STRAND      406    411       {ECO:0000244|PDB:5FMV}.
FT   STRAND      418    425       {ECO:0000244|PDB:5FMV}.
FT   STRAND      427    436       {ECO:0000244|PDB:5FMV}.
FT   STRAND      441    444       {ECO:0000244|PDB:5FMV}.
FT   STRAND      452    468       {ECO:0000244|PDB:5FMV}.
FT   STRAND      472    477       {ECO:0000244|PDB:5FMV}.
FT   STRAND      487    497       {ECO:0000244|PDB:5FMV}.
FT   STRAND      499    504       {ECO:0000244|PDB:5FMV}.
FT   STRAND      516    539       {ECO:0000244|PDB:5FMV}.
FT   STRAND      547    555       {ECO:0000244|PDB:5FMV}.
FT   STRAND      564    569       {ECO:0000244|PDB:5FMV}.
FT   TURN        633    635       {ECO:0000244|PDB:1YGR}.
FT   HELIX       636    656       {ECO:0000244|PDB:1YGR}.
FT   STRAND      663    665       {ECO:0000244|PDB:1YGR}.
FT   TURN        668    670       {ECO:0000244|PDB:1YGR}.
FT   HELIX       673    678       {ECO:0000244|PDB:1YGR}.
FT   TURN        688    690       {ECO:0000244|PDB:1YGR}.
FT   STRAND      691    693       {ECO:0000244|PDB:1YGR}.
FT   STRAND      698    700       {ECO:0000244|PDB:1YGR}.
FT   TURN        701    704       {ECO:0000244|PDB:1YGR}.
FT   STRAND      705    711       {ECO:0000244|PDB:1YGR}.
FT   STRAND      714    716       {ECO:0000244|PDB:1YGR}.
FT   STRAND      720    723       {ECO:0000244|PDB:1YGR}.
FT   TURN        728    730       {ECO:0000244|PDB:1YGR}.
FT   HELIX       731    740       {ECO:0000244|PDB:1YGR}.
FT   STRAND      745    748       {ECO:0000244|PDB:1YGR}.
FT   STRAND      752    754       {ECO:0000244|PDB:1YGR}.
FT   STRAND      757    759       {ECO:0000244|PDB:1YGR}.
FT   TURN        767    769       {ECO:0000244|PDB:1YGR}.
FT   STRAND      771    774       {ECO:0000244|PDB:1YGR}.
FT   STRAND      777    786       {ECO:0000244|PDB:1YGR}.
FT   STRAND      788    802       {ECO:0000244|PDB:1YGR}.
FT   STRAND      807    814       {ECO:0000244|PDB:1YGR}.
FT   HELIX       826    836       {ECO:0000244|PDB:1YGR}.
FT   STRAND      847    850       {ECO:0000244|PDB:1YGR}.
FT   STRAND      852    855       {ECO:0000244|PDB:1YGR}.
FT   HELIX       856    869       {ECO:0000244|PDB:1YGR}.
FT   HELIX       871    874       {ECO:0000244|PDB:1YGR}.
FT   STRAND      875    877       {ECO:0000244|PDB:1YGR}.
FT   HELIX       879    887       {ECO:0000244|PDB:1YGR}.
FT   HELIX       897    913       {ECO:0000244|PDB:1YGR}.
FT   HELIX       920    922       {ECO:0000244|PDB:1YGR}.
FT   HELIX       923    930       {ECO:0000244|PDB:1YGR}.
FT   HELIX       941    948       {ECO:0000244|PDB:1YGR}.
FT   HELIX       960    962       {ECO:0000244|PDB:1YGR}.
FT   HELIX       966    968       {ECO:0000244|PDB:1YGR}.
FT   TURN        979    981       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1018   1022       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1029   1034       {ECO:0000244|PDB:1YGR}.
FT   TURN       1038   1040       {ECO:0000244|PDB:1YGR}.
FT   HELIX      1041   1050       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1055   1058       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1062   1064       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1067   1070       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1088   1093       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1095   1105       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1113   1120       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1125   1127       {ECO:0000244|PDB:1YGR}.
FT   HELIX      1132   1143       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1163   1171       {ECO:0000244|PDB:1YGR}.
FT   HELIX      1174   1189       {ECO:0000244|PDB:1YGR}.
FT   STRAND     1190   1192       {ECO:0000244|PDB:1YGR}.
FT   HELIX      1195   1205       {ECO:0000244|PDB:1YGR}.
FT   TURN       1207   1210       {ECO:0000244|PDB:1YGR}.
FT   HELIX      1213   1225       {ECO:0000244|PDB:1YGR}.
SQ   SEQUENCE   1304 AA;  147254 MW;  A08FC22D6069BAF7 CRC64;
     MYLWLKLLAF GFAFLDTEVF VTGQSPTPSP TGLTTAKMPS VPLSSDPLPT HTTAFSPAST
     FERENDFSET TTSLSPDNTS TQVSPDSLDN ASAFNTTGVS SVQTPHLPTH ADSQTPSAGT
     DTQTFSGSAA NAKLNPTPGS NAISDVPGER STASTFPTDP VSPLTTTLSL AHHSSAALPA
     RTSNTTITAN TSDAYLNASE TTTLSPSGSA VISTTTIATT PSKPTCDEKY ANITVDYLYN
     KETKLFTAKL NVNENVECGN NTCTNNEVHN LTECKNASVS ISHNSCTAPD KTLILDVPPG
     VEKFQLHDCT QVEKADTTIC LKWKNIETFT CDTQNITYRF QCGNMIFDNK EIKLENLEPE
     HEYKCDSEIL YNNHKFTNAS KIIKTDFGSP GEPQIIFCRS EAAHQGVITW NPPQRSFHNF
     TLCYIKETEK DCLNLDKNLI KYDLQNLKPY TKYVLSLHAY IIAKVQRNGS AAMCHFTTKS
     APPSQVWNMT VSMTSDNSMH VKCRPPRDRN GPHERYHLEV EAGNTLVRNE SHKNCDFRVK
     DLQYSTDYTF KAYFHNGDYP GEPFILHHST SYNSKALIAF LAFLIIVTSI ALLVVLYKIY
     DLHKKRSCNL DEQQELVERD DEKQLMNVEP IHADILLETY KRKIADEGRL FLAEFQSIPR
     VFSKFPIKEA RKPFNQNKNR YVDILPYDYN RVELSEINGD AGSNYINASY IDGFKEPRKY
     IAAQGPRDET VDDFWRMIWE QKATVIVMVT RCEEGNRNKC AEYWPSMEEG TRAFGDVVVK
     INQHKRCPDY IIQKLNIVNK KEKATGREVT HIQFTSWPDH GVPEDPHLLL KLRRRVNAFS
     NFFSGPIVVH CSAGVGRTGT YIGIDAMLEG LEAENKVDVY GYVVKLRRQR CLMVQVEAQY
     ILIHQALVEY NQFGETEVNL SELHPYLHNM KKRDPPSEPS PLEAEFQRLP SYRSWRTQHI
     GNQEENKSKN RNSNVIPYDY NRVPLKHELE MSKESEHDSD ESSDDDSDSE EPSKYINASF
     IMSYWKPEVM IAAQGPLKET IGDFWQMIFQ RKVKVIVMLT ELKHGDQEIC AQYWGEGKQT
     YGDIEVDLKD TDKSSTYTLR VFELRHSKRK DSRTVYQYQY TNWSVEQLPA EPKELISMIQ
     VVKQKLPQKN SSEGNKHHKS TPLLIHCRDG SQQTGIFCAL LNLLESAETE EVVDIFQVVK
     ALRKARPGMV STFEQYQFLY DVIASTYPAQ NGQVKKNNHQ EDKIEFDNEV DKVKQDANCV
     NPLGAPEKLP EAKEQAEGSE PTSGTEGPEH SVNGPASPAL NQGS
//
